Zealand Pharma (ZEAL) Stock Overview
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ZEAL Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Zealand Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 486.30 |
| 52 Week High | DKK 809.00 |
| 52 Week Low | DKK 306.10 |
| Beta | 0.54 |
| 1 Month Change | -5.32% |
| 3 Month Change | 13.83% |
| 1 Year Change | -39.44% |
| 3 Year Change | 151.97% |
| 5 Year Change | 122.66% |
| Change since IPO | 511.70% |
Recent News & Updates
Zealand Pharma (CPH:ZEAL) Has A Rock Solid Balance Sheet
Dec 11
Zealand Pharma A/S (CPH:ZEAL) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 16Recent updates
Zealand Pharma (CPH:ZEAL) Has A Rock Solid Balance Sheet
Dec 11Zealand Pharma A/S (CPH:ZEAL) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 16Zealand Pharma A/S' (CPH:ZEAL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Aug 29
Clinical Catalysts And Roche Alliance Will Advance Obesity Amid Risks
Key Takeaways Major data from obesity drug trials and new industry alliances position the company for expanded future revenues, lowered commercialization risks, and greater global market access. Strong financial reserves enable self-funded innovation and product launches, with pipeline diversification aligning well with emerging trends in obesity treatment.Analysts Are Updating Their Zealand Pharma A/S (CPH:ZEAL) Estimates After Its First-Quarter Results
Aug 17Is Zealand Pharma (CPH:ZEAL) Weighed On By Its Debt Load?
May 24Most Shareholders Will Probably Find That The CEO Compensation For Zealand Pharma A/S (CPH:ZEAL) Is Reasonable
Mar 21Zealand Pharma A/S (CPH:ZEAL) Analysts Are Way More Bearish Than They Used To Be
Feb 21Analysts Just Made A Substantial Upgrade To Their Zealand Pharma A/S (CPH:ZEAL) Forecasts
Dec 22Shareholder Returns
| ZEAL | DK Biotechs | DK Market | |
|---|---|---|---|
| 7D | -7.4% | -2.1% | 3.8% |
| 1Y | -39.4% | 9.0% | -33.5% |
Return vs Industry: ZEAL underperformed the Danish Biotechs industry which returned 9% over the past year.
Return vs Market: ZEAL underperformed the Danish Market which returned -33.5% over the past year.
Price Volatility
| ZEAL volatility | |
|---|---|
| ZEAL Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in DK Market | 10.0% |
| 10% least volatile stocks in DK Market | 2.6% |
Stable Share Price: ZEAL's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: ZEAL's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 440 | Adam Steensberg | www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Zealand Pharma A/S Fundamentals Summary
| ZEAL fundamental statistics | |
|---|---|
| Market cap | DKK 34.18b |
| Earnings (TTM) | DKK 6.54b |
| Revenue (TTM) | DKK 9.16b |
Is ZEAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZEAL income statement (TTM) | |
|---|---|
| Revenue | DKK 9.16b |
| Cost of Revenue | DKK 1.22m |
| Gross Profit | DKK 9.15b |
| Other Expenses | DKK 2.61b |
| Earnings | DKK 6.54b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 19, 2026
| Earnings per share (EPS) | 93.09 |
| Gross Margin | 99.99% |
| Net Profit Margin | 71.47% |
| Debt/Equity Ratio | 2.0% |
How did ZEAL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 22:24 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zealand Pharma A/S is covered by 35 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yihan Li | Barclays |
| Laura Hindley | Berenberg |
| Kerry Holford | Berenberg |